These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38752508)

  • 21. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
    Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
    JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau.
    Butt OH; Meeker KL; Wisch JK; Schindler SE; Fagan AM; Benzinger TLS; Cruchaga C; Holtzman DM; Morris JC; Ances BM
    Alzheimers Dement; 2022 Jan; 18(1):116-126. PubMed ID: 34002449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High cholesterol levels change the association of biomarkers of neurodegenerative diseases with dementia risk: Findings from a population-based cohort.
    Perna L; Mons U; Stocker H; Beyer L; Beyreuther K; Trares K; Holleczek B; Schöttker B; Perneczky R; Gerwert K; Brenner H
    Alzheimers Dement; 2023 Jul; 19(7):2913-2922. PubMed ID: 36638231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
    Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
    Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
    Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO
    Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease.
    Petersen KK; Ezzati A; Lipton RB; Gordon BA; Hassenstab J; Morris JC; Grober E
    J Prev Alzheimers Dis; 2023; 10(1):112-119. PubMed ID: 36641615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
    Saddiki H; Fayosse A; Cognat E; Sabia S; Engelborghs S; Wallon D; Alexopoulos P; Blennow K; Zetterberg H; Parnetti L; Zerr I; Hermann P; Gabelle A; Boada M; Orellana A; de Rojas I; Lilamand M; Bjerke M; Van Broeckhoven C; Farotti L; Salvadori N; Diehl-Schmid J; Grimmer T; Hourregue C; Dugravot A; Nicolas G; Laplanche JL; Lehmann S; Bouaziz-Amar E; ; Hugon J; Tzourio C; Singh-Manoux A; Paquet C; Dumurgier J
    PLoS Med; 2020 Aug; 17(8):e1003289. PubMed ID: 32817639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
    Schindler SE; Karikari TK; Ashton NJ; Henson RL; Yarasheski KE; West T; Meyer MR; Kirmess KM; Li Y; Saef B; Moulder KL; Bradford D; Fagan AM; Gordon BA; Benzinger TLS; Balls-Berry J; Bateman RJ; Xiong C; Zetterberg H; Blennow K; Morris JC
    Neurology; 2022 Jul; 99(3):e245-e257. PubMed ID: 35450967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
    Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25.
    Butt OH; Long JM; Henson RL; Herries E; Sutphen CL; Fagan AM; Cruchaga C; Ladenson JH; Holtzman DM; Morris JC; Ances BM; Schindler SE;
    Neurobiol Aging; 2021 Jun; 102():64-72. PubMed ID: 33765432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.
    Guo T; Li A; Sun P; He Z; Cai Y; Lan G; Liu L; Li J; Yang J; Zhu Y; Zhao R; Chen X; Shi D; Liu Z; Wang Q; Xu L; Zhou L; Ran P; Wang X; Sun K; Lu J; Han Y
    Mol Neurodegener; 2024 Jul; 19(1):58. PubMed ID: 39080744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
    Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
    Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Astrocytic function is associated with both amyloid-β and tau pathology in non-demented
    Spotorno N; Najac C; Stomrud E; Mattsson-Carlgren N; Palmqvist S; van Westen D; Ronen I; Hansson O
    Brain Commun; 2022; 4(3):fcac135. PubMed ID: 35702728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting amyloid PET and tau PET stages with plasma biomarkers.
    Jack CR; Wiste HJ; Algeciras-Schimnich A; Figdore DJ; Schwarz CG; Lowe VJ; Ramanan VK; Vemuri P; Mielke MM; Knopman DS; Graff-Radford J; Boeve BF; Kantarci K; Cogswell PM; Senjem ML; Gunter JL; Therneau TM; Petersen RC
    Brain; 2023 May; 146(5):2029-2044. PubMed ID: 36789483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.